[{"address1": "12790 El Camino Real", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "760 593 4832", "website": "https://ventyxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.", "fullTimeEmployees": 75, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sheila K. Gujrathi M.D.", "age": 54, "title": "Executive Chairperson", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 125000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raju S. Mohan Ph.D.", "age": 66, "title": "Founder, CEO, President & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 905293, "exercisedValue": 0, "unexercisedValue": 219686}, {"maxAge": 1, "name": "Dr. John M. Nuss Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 630635, "exercisedValue": 0, "unexercisedValue": 451580}, {"maxAge": 1, "name": "Mr. Roy M. Gonzales CPA, M.B.A.", "age": 49, "title": "Interim Principal Financial Officer & Principal Accounting Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Richard Moore", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark S. Forman M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.25, "open": 2.13, "dayLow": 2.07, "dayHigh": 2.1892, "regularMarketPreviousClose": 2.25, "regularMarketOpen": 2.13, "regularMarketDayLow": 2.07, "regularMarketDayHigh": 2.1892, "beta": 0.366, "forwardPE": -0.985782, "volume": 884874, "regularMarketVolume": 884874, "averageVolume": 1637385, "averageVolume10days": 2249460, "averageDailyVolume10Day": 2249460, "bid": 1.55, "ask": 2.67, "bidSize": 200, "askSize": 200, "marketCap": 147078256, "fiftyTwoWeekLow": 1.67, "fiftyTwoWeekHigh": 11.48, "fiftyDayAverage": 2.2862, "twoHundredDayAverage": 2.924875, "currency": "USD", "enterpriseValue": -116710816, "floatShares": 49721620, "sharesOutstanding": 70710704, "sharesShort": 8634544, "sharesShortPriorMonth": 8552041, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.1221, "heldPercentInsiders": 0.044899996, "heldPercentInstitutions": 0.84688, "shortRatio": 4.15, "shortPercentOfFloat": 0.1429, "impliedSharesOutstanding": 70710704, "bookValue": 3.945, "priceToBook": 0.5272497, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -152524000, "trailingEps": -2.35, "forwardEps": -2.15, "enterpriseToEbitda": 0.703, "52WeekChange": -0.02803737, "SandP52WeekChange": 0.22263205, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "VTYX", "underlyingSymbol": "VTYX", "shortName": "Ventyx Biosciences, Inc.", "longName": "Ventyx Biosciences, Inc.", "firstTradeDateEpochUtc": 1634823000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f523c464-d79a-3f62-beea-fdbd09f3b782", "messageBoardId": "finmb_672535556", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.08, "targetHighPrice": 21.0, "targetLowPrice": 2.0, "targetMeanPrice": 11.14286, "targetMedianPrice": 11.0, "recommendationMean": 1.77778, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 274824992, "totalCashPerShare": 3.887, "ebitda": -166116992, "totalDebt": 11036000, "quickRatio": 22.371, "currentRatio": 23.523, "debtToEquity": 3.959, "returnOnAssets": -0.33393002, "returnOnEquity": -0.54239, "freeCashflow": -100833248, "operatingCashflow": -159279008, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]